EU/3/08/560: Orphan designation for the treatment of moderate and severe closed traumatic brain injury

(-)-(2R)-3-(2-hydroxymethylindanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate

Table of contents

Overview

On 5 September 2008, orphan designation (EU/3/08/560) was granted by the European Commission to KeyNeurotek Pharmaceuticals AG, Germany, for (-)-(2R)-3-(2-hydroxymethylindanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate for the treatment of moderate and severe closed traumatic brain injury.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
(-)-(2R)-3-(2-hydroxymethylindanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate
Intended use
Treatment of moderate and severe closed traumatic brain injury
Orphan designation status
Positive
EU designation number
EU/3/08/560
Date of designation
05/09/2008
Sponsor
KeyNeurotek Pharmaceuticals AG
Zenit-Technology Park
Leipzigerstr. 44
39120 Magdeburg
Germany
Tel. + 49 391 6117 220
Gax: + 49 391 6117 221

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating